

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

August 18, 2020

Sergio Traversa Chief Executive Officer Relmada Therapeutics, Inc. 880 Third Avenue, 12th Floor New York, NY 10022

> Re: Relmada Therapeutics, Inc. Registration Statement on Form S-3 Filed August 12, 2020 File No. 333-245054

Dear Mr. Traversa:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Deanna Virginio at 202-551-4530 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Barrett DiPaolo, Esq.